ADVFN Logo

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

BCART

Biocartis Group NV (BCART)

Biocartis Group NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:BCART
DatumZeitQuelleÜberschriftSymbolFirma
10/01/202423h00GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)EU:BCARTBiocartis Group NV
10/01/202423h00GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)EU:BCARTBiocartis Group NV
22/11/202310h00GlobeNewswire Inc.Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansionEU:BCARTBiocartis Group NV
13/11/202307h00GlobeNewswire Inc.Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual MeetingEU:BCARTBiocartis Group NV
31/10/202315h55GlobeNewswire Inc.Press release Biocartis Group NV: Announcement regarding Enforcement by Secured CreditorsEU:BCARTBiocartis Group NV
20/10/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)EU:BCARTBiocartis Group NV
16/10/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer PortfolioEU:BCARTBiocartis Group NV
12/10/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations KitEU:BCARTBiocartis Group NV
03/10/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Disclosure of transparency notificationEU:BCARTBiocartis Group NV
26/09/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalizationEU:BCARTBiocartis Group NV
26/09/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding companyEU:BCARTBiocartis Group NV
21/09/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023EU:BCARTBiocartis Group NV
28/08/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leadersEU:BCARTBiocartis Group NV
24/08/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023EU:BCARTBiocartis Group NV
10/08/202307h00GlobeNewswire Inc.Press Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ PlatformEU:BCARTBiocartis Group NV
18/07/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service DeliveryEU:BCARTBiocartis Group NV
30/06/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of Outstanding Voting SecuritiesEU:BCARTBiocartis Group NV
20/06/202317h40GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of transparency notificationEU:BCARTBiocartis Group NV
15/06/202317h15GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis announces planned operational reorganization and cost reduction programEU:BCARTBiocartis Group NV
08/06/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of transparency notificationEU:BCARTBiocartis Group NV
05/06/202317h40GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis announces resignation CFOEU:BCARTBiocartis Group NV
12/05/202317h40GlobeNewswire Inc.Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 12 May 2023EU:BCARTBiocartis Group NV
09/05/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis and HiloProbe to Collaborate on Colorectal Cancer TestEU:BCARTBiocartis Group NV
28/04/202317h40GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of Outstanding Voting SecuritiesEU:BCARTBiocartis Group NV
20/04/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis Reports Results of First Quarter of 2023EU:BCARTBiocartis Group NV
11/04/202322h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEOEU:BCARTBiocartis Group NV
11/04/202307h01GlobeNewswire Inc.Press release Biocartis Group NV: Invitation to the Annual Shareholders’ MeetingEU:BCARTBiocartis Group NV
11/04/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis Announces Publication of 2022 Annual ReportEU:BCARTBiocartis Group NV
04/04/202307h00GlobeNewswire Inc.Press release Biocartis Group NV: Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platformEU:BCARTBiocartis Group NV
31/03/202317h40GlobeNewswire Inc.Press release Biocartis Group NV: Disclosure of Outstanding Voting SecuritiesEU:BCARTBiocartis Group NV
 Showing the most relevant articles for your search:EU:BCART
Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

Support: +44 (0) 203 8794 460 | support@advfn.de